{rfName}
Si

Indexed in

Altmetrics

Analysis of institutional authors

Vidal-Torres, AlbaAuthor

Share

July 5, 2013
Publications
>
Article
No

Sigma-1 receptor antagonism as opioid adjuvant strategy: Enhancement of opioid antinociception without increasing adverse effects

Publicated to: EUROPEAN JOURNAL OF PHARMACOLOGY. 711 (1-3): 63-72 - 2013-07-05, DOI: 10.1016/j.ejphar.2013.04.018

Authors:

Vidal-Torres, Alba; de la Puente, Beatriz; Rocasalbas, Maria; Tourino, Clara; Andreea Bura, Simona; Fernandez-Pastor, Begona; Romero, Luz; Codony, Xavier; Zamanillo, Daniel; Merlos, Manuel; Manuel Baeyens, Jose; Maldonado, Rafael; Miguel Vela, Jose
[+]

Affiliations

Esteve, Drug Discovery & Preclin Dev, Barcelona 08028, Spain - Author
Univ Granada, Fac Med, Dept Pharmacol, Granada 18012, Spain - Author
Univ Granada, Fac Med, Inst Neurosci, Granada 18012, Spain - Author
Univ Pompeu Fabra, Barcelona 08003, Spain - Author
See more

Abstract

While opioids are potent analgesics widely used in the management of pain, a number of well-known adverse effects limit their use. The sigma-1 receptor is a ligand-regulated molecular chaperone involved in pain processing, including modulation of opioid antinociception. However, data supporting the potential use of sigma-1 receptor ligands as suitable opioid adjuvants are based on studies that use non selective ligands. Also, safety issues derived from combination therapy are poorly addressed. In this study we used the new selective sigma-1 receptor antagonist S1RA (E-52862) to characterize the effect of selective sigma-1 receptor blockade on opioid-induced efficacy- and safety-related outcomes in mice. S1RA (40 mg/kg) had no effect in the tail-flick test but did enhance the antinociceptive potency of several opioids by a factor between 2 and 3.3. The potentiating effect of S1RA on morphine antinociception did not occur in sigma-1 receptor knockout mice, which supports the selective involvement of the sigma-1 receptor. Interestingly, S1RA co-administration restored morphine antinociception in tolerant mice and reverted the reward effects of morphine in the conditioned place preference paradigm. In addition, enhancement of antinociception was not accompanied by potentiation of other opioid-induced effects, such as the development of morphine analgesic tolerance, physical dependence, inhibition of gastrointestinal transit, or mydriasis. The use of sigma-1 receptor antagonists as opioid adjuvants could represent a promising pharmacological strategy to enhance opioid potency and, most importantly, to increase the safety margin of opioids. S1RA is currently in phase II clinical trials for the treatment of several pain conditions. (c) 2013 Elsevier B.V. All rights reserved.
[+]

Keywords

4 [2 [5 methyl 1 (naphthalen 2 yl) 1h pyrazol 3 yloxy]ethyl]morpholineAdjuvant therapyAdverse drug reactionAnalgesiaAnalgesics, opioidAnimal experimentAnimal modelAnimalsAntinociceptionArticleBehavior, animalBrainBuprenorphineChemotherapy, adjuvantCodeineConditioned place preferenceConditioning (psychology)Conditioning, psychologicalControlled studyDesensitizationDrug dependenceDrug efficacyDrug potencyDrug potentiationDrug safetyDrug synergismDrug toleranceE 52862Fentanyl citrateGastrointestinal transitGene knockout techniquesIntestinesInvolvementMaleMethyl-d-aspartateMiceMorphineMouseMydriasisNaloxoneNeuropathic painNonhumanOpiateOpiate antagonistOpioid adjuvantOxycodonePainPhosphorylationPkc-alphaPriority journalReceptor blockingReceptors, sigmaRewardS1ra (e-52862)Sigma 1 opiate receptorSigma-1 receptorSpatial behaviorTail flick testToleranceTramadolUnclassified drug

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal EUROPEAN JOURNAL OF PHARMACOLOGY due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2013, it was in position 98/256, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Pharmacology & Pharmacy. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Pharmacology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.33. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 2.31 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-11-16, the following number of citations:

  • WoS: 77
  • Scopus: 78
  • Europe PMC: 52
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-11-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 64.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 64 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Germany.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Vidal Torres, Alba) .

[+]

Awards linked to the item

S1RA was provided by Esteve as a gift within research projects supported by Grants from the Centro para el Desarrollo Tecnologico Industrial of the Spanish Ministry of Science, Technology and Innovation (Grant Numbers CEN-20061005 and IDI-20110590).
[+]